Gabapentin and lamotrigine: Prescribing guidelines for psychiatry

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 6, 1997, Pages 334-342

  Semenchuk, Marilyn R ^a,b   Labiner, David M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b College of Medicine and Pharmacy ^*  (United States)

Author keywords

Anticonvulsants; Bipolar disorder; Gabapentin; Lamotrigine

Indexed keywords

EID: 0001011355     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271: 918-24.
2. Kahn DA, Ross R, Rush AJ, et al. Expert consensus treatment guidelines for bipolar disorder. J Clin Psychiatry 1996;57(suppl 12A).
3. Dilsaver SC, Swann AC, Shoaib AM, et al. The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. J Psych Neurosci 1993;18(2):61-6.
4. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992;12:53-6.
5. Tohen M, Castillo J, Pope HG Jr, et al. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:67-70.
6. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35(3):249-50.
7. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989;50S:44-8.
8. Schweizer E, Rickels K, Case WG, et al. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48:448-52.
9. Galpern WR, Miller LG, Greenblatt DJ, et al. Attenuation of alprazolam discontinuation effects by carbamazepine. Biochem Pharmacol 1991;42S:S99-S104.
10. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-9.
11. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc 1992;40:914-6.
12. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbances in dementia. J Geriatr Psychiatry Neurol 1993;6:205-9.
13. Leibovici A, Tariot N. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol 1988;1:110-2.
14. MacDonald RL. Carbamazepine: Mechanism of action. In: Antiepileptic Drugs. Levy RH, Mattson RH, Meldrum BS (eds), 4th ed. New York: Raven Press; 1995:491-8.
15. Cross JA, Cheetham SC, Crompton MR, et al. Brain GABA binding sites in depressed suicide victims. Psychiatry Res 1988;26:119-29.
16. Enna SJ. The role of gamma-aminobutyric acid in anxiety. Psychopathology 1984;17:15-24.
17. Kasa K, Otsuki S, Yamamoto M, et al. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 1982;17:877-83.
18. Garafalo E, Hayes A, Greeky C, et al. Gabapentin (neurontin) monotherapy in patients with medically refractory seizures: An open-label extension study. Epilepsia 1995;36(suppl 3):S119-S120.
19. Gotz E, Feuerstein TJ, Lais A, et al. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43:636-8.
20. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39(1):95-9.
21. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994;44(supp 5):S10-S16.
22. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin) binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
23. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997;58:224-42.
24. Bruni J. Gabapentin. Can J Neurol Sci 1996;23(suppl 2):S10-S12.
25. Neurontin Product Monograph, Parke-Davis, Morris Plains, NJ, 1996.
26. Comstock JT, Sica DA, Bockbrader HN, et al. Gabapentin pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 1990;30:862.
27. Bruni J, Saunders M, Anhut H, et al. Efficacy and safety of gabapentin (Neurontin): A multicenter, placebo-controlled, double-blind study. Neurology 1991;41(suppl 1):330-1.
28. Browne TR. United States, International, and Parke-Davis Gabapentin Study Groups. Long-term efficacy and toxicity of gabapentin. Neurology 1993;43:A307.
29. Ojemann LM, Wilenshy AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992;13:159-65.
30. Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994;44(suppl 5):S23-S30.
31. Arnett JL, Dodrill CB. Effects of gabapentin (GBP, Neurontin) on cognitive functioning and mood. Epilepsia 1995;35(suppl 3):S32.
32. Asconape J, Collins T. Weight gain associated with the use of gabapentin. Epilepsia 1995;36(suppl 4):S72.
33. Cugley AL, Swartz BE. Gabapentin-associated mood changes? Epilepsia 1995;36(suppl 4):S72.
34. Schantz D, Towbin JA, Spitz MD. Changes in mood and affect in patients on gabapentin. Epilepsia 1995;36(suppl 4):S73.
35. Zupane ML, Schroeder VM. Behavioral changes in children on gabapentin. Epilepsia 1995;36(suppl 4):S73.
36. Reeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-90.
37. Busch JA, Radulovic LL, Bockbrader HN, et al. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects. Pharm Res 1992;9(suppl 1);S31.
38. Dimond KR, Pande AC, Lamoreaux L, et al. Effect of gabapentin (neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:407-17.
39. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997;154(2):291-2.
40. Marcotte DB. Gabapentin: An effective therapy for patients with bipolar affective disorder. Abstract #NR261 presented at the American Psychiatric Association Annual Meeting, San Diego, May 17-22, 1997.
41. Young LT. Gabapentin in bipolar depression: A case series. Abstract #NR452 presented at the American Psychiatric Association Annual Meeting, San Diego, May 17-22, 1997.
42. Regan WM, Gordon SM. Gabapentin for behavioral agitation in Alzheimer's disease. J Clin Psychopharmacol 1997;17(1):59-60.
43. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry 1996;152(9):1399.
44. Wilder BJ. Antiepileptic drugs - current use. Can J Neurol Sci 1996;23(suppl 2):S18-S23.
45. Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
46. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: 2 neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7.
47. Lamictal Product Monograph, GlaxoWellcome, Research Triangle Park, NC, 1997.
48. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185-9.
49. Kaspar S. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10(supp 4):25-35.
50. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
51. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect-toxicity relationships with lamotrigine - a prospective study. Epilepsia 1996;37:534-8.
52. Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-50.
53. Gilman JT. Lamotrigine: An antiepileptic agent for the treatment of partial seizures. Ann Pharmacother 1995;29:144-51.
54. Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine. Epilepsia 1991;32(suppl 2):S17-21.
55. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
56. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
57. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-1400.
58. Depot M, Powell JR, Messenheimer JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-55.
59. Calabrese JR, Woyshville M, Bowden C, et al. Spectrum of efficacy of lamotrigine in treatment-refractory manic depression. Abstr. 2nd International Conference on Affective Disorders. Jerusualem, 1995.
60. Weisler R, Risner ME, Ascher J, et al. Use of lamotrigine in the treatment of bipolar disorder. Abstr. American Psychiatric Association. Philadelphia 1994.
61. Walden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996;29:193-5.
62. Brodie MJ. Lamotrigine - an update. Can J Neurol Sci 1996;23(suppl 2):S6-S9.
63. Mims J, Penovich P, Ritter F, et al. Treatment with high doses of lamotrigine in children and adolescents with refractory seizures. J Child Neurol 1997;12(1):64-7.
64. Matsuo F, Madsen J, Tolman KG, et al. Lamotrigine high-dose tolerability and safety in patients with epilepsy: A double-blind, placebo-controlled, eleven-week study. Epilepsia 1996;37:857-62.